

MARSHALL C. FREEMAN, MD
FAHS, FAAN, FAANEM
Headache Wellness Center
1414 Yanceyville Street
Greensboro, NC 27405
Tel: 336-574-8000 Fax: 336-574-8008

CURRENT

Director	Headache Wellness Center Greensboro, NC
Director & Chief Medical Officer	Headache Wellness Center Research Greensboro, NC
Director	EMG-EEG Consultants Greensboro, NC

EDUCATION

Fellowship Clinical Neurophysiology Neuromuscular Diseases 1999-2000	Division of Neuromuscular Diseases Eleanor and Lou Gehrig MDA/ALS Center Neurological Institute Columbia University College of Physicians and Surgeons New York, NY
Residency Adult Neurology 1996-1999	Neurological Institute Columbia University College of Physicians and Surgeons New York, NY
Internship 1995-1996	University of Michigan Hospitals Oakwood Hospital Dearborn, MI
Medical Education Doctor of Medicine 1991-1995	Wayne State University College of Medicine Detroit, MI
Graduate Education Master of Science, Biology 1989-1991	University of Michigan Horace H. Rackham School of Graduate Studies Ann Arbor, MI
Undergraduate Education Bachelor of Science, Biology 1985-1989	University of Michigan College of Literature, Science, and Arts Ann Arbor, MI

PROFESSIONAL RECOGNITIONS

Fellow, American Headache Society (FAHS)
Fellow, American Academy of Neurology (FAAN)
Fellow, American Association of Neuromuscular & Electrodiagnostic Medicine (FAANEM)

PROFESSIONAL MEMBERSHIPS

American Academy of Neurology (AAN)
American Headache Society (AHS)
International Headache Society (IHS)
North Carolina Neurological Society (NCNS)
Southern Headache Society (SHS)
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
American College of Physicians (ACP)

ACADEMIC APPOINTMENTS

Assistant in Clinical Neurology, Department of Neurology, Columbia University, College of Physicians and Surgeons, New York, NY (1999-2000)

PROFESSIONAL CERTIFICATIONS

Diplomate, American Board of Psychiatry and Neurology, **Neurology**, Certification 48267
Diplomate, National Board of Physicians and Surgeons, **Neurology**, Certification 008863
Diplomate, American Board of Electrodiagnostic Medicine, **Electrodiagnostic Medicine**
Certification 2792
Diplomate, United Council for Neurologic Subspecialties, **Headache Medicine**,
Certification HM00223-06
Diplomate, National Board of Physicians and Surgeons, **Headache Medicine**,
Certification 008863
Diplomate, American Board of Psychiatry and Neurology, **Neuromuscular Medicine**,
Certification 229
Diplomate, National Board of Physicians and Surgeons, **Neuromuscular Medicine**,
Certification, 008863

PROFESSIONAL ACTIVITIES

Practice Management Committee, American Headache Society
Bylaws Committee, American Headache Society
Education Committee, Southern Headache Society
Examination Committee Board, United Council for Neurologic Subspecialties (UCNS)
Ad Hoc Reviewer, Headache, American Headache Society
Ad Hoc Reviewer, Headache Currents

Abstract Review Committee, American Academy of Neurology
Leadership in Advocacy Development (LEAD), American Headache Society
Resident Education for Assessment and Care for Headache (REACH),
American Headache Society
Headache and Facial Pain Section, American Academy of Neurology
Alliance for Headache Disorders Advocacy (AHDA)
Neurology on the Hill, American Academy of Neurology
Headache on the Hill, American Headache Society
Medical Course Director, Southern Headache Society (2025)
NeurologyLive, Advisory Board

ACCREDITATIONS

Exemplary Status, American Association of Neuromuscular & Electrodiagnostic
Medicine, EMG-EEG Consultants

CLINICAL RESEARCH AND COMPLIANCE TRAINING

International Council for Harmonization-Good Clinical Practice (ICH-GCP)
Columbia-Suicide Severity Rating Scale (C-SSRS) Rater Training
NIH: Principles and Practice of Clinical Research
Human Subjects Research Certification
HIPPA for Research Certification
Informed Consent Process and Research Documentation Certification
FDA Regulations for Clinical Investigators Training
Adverse Event and Serious Adverse Event Reporting Training
Clinical Trials Operations and Management

RESEARCH STUDIES

2025: Protocol: Kallyope: K645-P003: A Phase IIa, Multicenter, Randomized, Double-
Blind, Placebo-Controlled Crossover Study of K-645 in the Treatment of Multiple
Migraine Attacks

2025: Protocol: Pfizer: C5301023: A Phase 1, Multicenter, Open-Label, Single-Dose
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Zavegepant in
Children 6 to less than 12 years of age with History of Migraine

2025: Protocol: Kallyope: K304 P001: A Phase 2B, Randomized, Double-Blind, Placebo-
Controlled, Dose-Ranging Study of Elismetrep (K-304) in the Treatment of Migraine

2024: Protocol: AbbVie: M23-712: A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age (HORIZON)

2024: Protocol: Lundbeck: LUND-20668A: Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants with Migraine and Previous Inadequate Response to CGRP-targeting Therapies (THRIVE)

2024: Protocol: Ipsen: CLIN-52120-464 (276231): A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants (C-BEOND)

2024: Protocol: Ipsen: CLIN-52120-463(276201), A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants (E-BEOND)

2024: Protocol: AbbVie: M24-873: AGN-151607-DP (gemibotulinumtoxinA) for the Preventive Treatment of Migraine in Adults: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Program (PURSUE)

2024: Protocol: Lundbeck: LUND-20297A: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding Trial of Lu AG09222 for the Prevention of Migraine in Participants with Unsuccessful Prior Preventive Treatments (PROCEED)

2024: Protocol: AbbVie: M23-714: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Treatment of Menstrual Migraine with an Open-Label Extension (MOSAIC)

2023: Protocol: AbbVie: M21-199: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

2023: Protocol: AbbVie: 3101-312-002: A Phase 3, Multicenter, Open-Label 156-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

2023: Protocol: AbbVie: M21-201: A Phase 3, Multicenter, 12-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6 to 17 Years of Age (KALEIDOSCOPE)

2022: Protocol: Biohaven: BHV 3000-407: A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications

2022: Protocol: Biohaven: BHV 3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Multiple Migraine Attacks in Adults Unsuitable for Triptan Use

2022: Protocol: AbbVie: M22-418: A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine (UNCHAINED)

2021: Protocol: AbbVie M21-307: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects With Episodic Migraine (PRECLUDE)

2021: Protocol: Currax 17-AVP-8250301: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Onzetra Xsail (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

2021: Protocol: Satsuma STS 101-007: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine (SUMMIT)

2021: Protocol: Biohaven BHV 3500-302: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

2021: Protocol: Allergan 3101-312-002: A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

2021: Protocol: Lundbeck: LUND19386A: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients with Episodic Cluster Headache (ALLEVIATE)

2021: Protocol: Biohaven: BHV 3000-312: A Phase 2, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

2020: Protocol: Biohaven BHV 3000-311: A Phase 3, Multicenter, Randomized, Double-Blind, Group Sequential, Placebo-Controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

2020: Protocol: Biohaven: BHV 3000-121: A Multicenter, Open-label, Single-Dose Study to Evaluate the Safety, Tolerability, and Single-Dose Pharmacokinetics of Rimegepant in Children (≥ 6 to < 12 Years of Age) With a History of Migraine

2020: Protocol: Biohaven: BHV 3500-301: A Phase 3 Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine

2020: Protocol: Eli Lilly: I5Q-MC-B004: Prospective, Multi-Center, International, 2-Stage Non-Interventional Study of Adult Patients with Migraine Who Are Switching Or Initiating New Preventive Treatments In Clinical Practice Settings (TRIUMPH)

2020: Protocol: Biohaven: BHV 3500-202: A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV 3500 (vezegepant) Intranasal (IN) for the Acute Treatment of Migraine

2019: Protocol: Amgen: AMG 20180060: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects with Episodic Migraine Who Have Previously Failed 1 or More Migraine Preventive Treatments

2019: Protocol: Satsuma: STS101-002: A Randomized Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine (EMERGE)

2019: Protocol: Biohaven: 3500-201: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraine

2019: Protocol: Allergan: 3101-303-002: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (PROGRESS)

2019: Protocol: Charleston Labs: CL02-204: A Multicenter, Randomized, Double-Blind, Comparator-Controlled, Placebo-Controlled Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine-Associated Nausea and Vomiting (MANV)

2018: Protocol: IPX229-B16-01: Impax: A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy and Safety of Zolmitriptan Nasal Spray for the Treatment of Acute Migraine in Subjects Ages 6 to 11 Years, with an Open-Label Extension

2017: Protocol: EVA-16821-000: A Prospective Observational Study to Evaluate Tolerability, Outcomes, and Treatment Patterns of Prophylactic Therapies in Migraine

2017: Protocol: AMG 334-20120178: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

2017: Protocol: Amgen 301 20150308: A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

2016: Protocol: AMG-2016-0343: An Observational Interview-based Study to Explore Perceptions of a Clinically Meaningful Change Experienced by Subjects During a Clinical Trial of Erenumab

2016: Protocol: Allergan: UBR-MD-02: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

2016: Protocol: Allergan: UBR-MD-04: A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura

2016: Protocol: AMG-2016-0343: An Observational Interview-Based Study to Explore Subjective Perceptions of Meaningful Changes in Physical Functioning Experienced by Participants in a Clinical Trial of Erenumab

2016: Protocol: CP-2016-001: A Randomized, Double-Blind, Multi-Center, Parallel-Group, Dose-Ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine (ZOTRIP)

2016: Protocol: DFN-11-CD-004: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Tolerability and Safety Study of DFN-11 Injection (Sumatriptan 3 mg) in Episodic Migraine With or Without Aura (RESTOR)

2016: Protocol: AGN11183: Qualitative Study for Development of Patient-Reported Outcome Measures in Migraine

2016: Protocol: TV48125-CNS-30049: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

2016: Protocol: TV48125-CNS-30050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

2016: Protocol: TV48125-CNS-30051: A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

2016: Protocol: Amgen Protocol 20150124: Prospective Cohort Study to Describe Patient-Reported Outcomes in Subjects with Migraine Eligible for Prophylaxis

2016: Protocol: ALD403-CLIN-006: A Parallel Group, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraines

2016: Protocol: ALD403-CLIN-006: An Open Label Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraines

2015: Protocol: Eli Lilly: 15Q-MC-CGAG: Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine (Evolve-1)

2015: Protocol: Amgen Protocol 20130255: An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

2015: Protocol: Amgen Protocol 20120296: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention (STRIVE)

2015: Protocol: GMA-US-NEU-0206: A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine (FORWARD)

2014: Protocol: GMA-BTX-CM-10-001: An Open-Label, Multicenter Study of the Long-Term Efficacy, Safety and Tolerability of BOTOX (onabotulinumtoxinA) for the Prophylaxis of Headaches in Adult Patients with Chronic Migraine (COMPEL)

2014: Protocol: LBR-101-022: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 with Placebo for the Preventive Treatment of Episodic Migraine

2014: Protocol: LBR-101-021: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 with Placebo for the Preventive Treatment of Chronic Migraine

2014: Protocol: Scion: A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache

2014 Protocol: AMG 334–20120295: A Phase 2, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

2013: Protocol: AMG 334-20120178: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

2013: Protocol: RH01649: A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Type Headache

2012: Protocol: GMA-BTX-CM-10-001: An Open-Label, Multicenter Study of the Long-term Efficacy, Safety, and Tolerability of BOTOX (onabotulinumtoxinA) for the Prophylaxis of Headaches in Adult Patients with Chronic Migraine

2012: Protocol: MK-1602: A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine

2011. Protocol: OPN-SUM-MIG-3302: A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally with the Bi-directional Device Compared with 100 mg Sumatriptan Tablets in Adults with Acute Migraine With or Without Aura

2011. Protocol: OPN-SUM-MIG-3301: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally with the Bi-directional Device Compared with 100 mg Sumatriptan Tablets in Adults with Acute Migraine With or Without Aura

2011: Protocol: SAV-MD-25: A Randomized Double-Blind Placebo Control Trial of Milnacipran for Migraine Pain

2010: Protocol: MK0974-065: A Study of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients

2010: Protocol: NP010-009: An Open-label Study to Evaluate the Safety of NP101, A Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

2010: Protocol: NP101-008: An Open-label Study to Evaluate the Safety of NP101, A Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

2010: Protocol: ZX001-0901: A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety, and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans

2009: Protocol: NXN-188-203: A Phase 2 Study of the Safety and Effectiveness of Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache with Aura

2009: Protocol: Caloric Vestibular Stimulation for Acute and Chronic Migraine

2009 Protocol: MK-0462-087 : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial To Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders

2009 Protocol: NP101-007.04: The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study

2009 Protocol: TXA110948: Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination tablet treatment on Blood Pressure when administered intermittently for Six Months for the Acute Treatment of Migraine Attacks, with or without Aura, in adults

2008 Protocol: DR-105-201: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo for the Management of Menstrually-Related Migraine Headaches

2008 Protocol: MK-0974: A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients with Stable Vascular Disease

2008 Protocol: MPX111381: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache

2008 Protocol: MAP 0004-CL-P301: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open-Label Extension

2008 Protocol: A Randomized, Controlled Trial Testing the Safety and Efficacy of an Ambulatory Biofeedback Device vs. General Relaxation Instruction for Chronic Migraine

2007 Protocol: SP906: A Multi-Center, Randomized, Double-Controlled Trial to Assess the Efficacy and Safety of 100mg/day and 300/day Lacosamide for Migraine Prophylaxis

2006 Protocol: Allergan 191622-079: A Multicenter Study Evaluating the Efficacy and Safety of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-label Extension Phase

2006 Protocol: PRO-51330: A Multi-Center, Prospective, Randomized, Double-Blind, Parallel Group, Single Dose, Placebo Controlled Study of the Efficacy and Safety of PRO-513 (50 MG Diclofenac Potassium Powder for Oral Solution) Compared to Placebo in Adult Subjects with Migraine Attacks

2006 Protocol: TXA107563: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Tolerability of Trexima (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults Diagnosed with Probable Migraine without Aura

2006 Protocol: TRX106571: A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects who Report Poor Response or Intolerance to Short Acting Triptans

2006 Protocol: E2007-A001-210: A Randomized, Double-Blind, Placebo-Controlled Multi-Centered, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis

2006 Protocol: MK0974-004: A Multicenter, Double-Blind, Placebo and Active-Controlled, Dose-Finding Study of MK-0974 in the Treatment of Acute Migraine

2006 Protocol: TRX103635: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase For the Acute Treatment of Multiple Migraine Attacks

2006 Protocol: LNP-201: A Randomized, Double-Blind, Single Dose, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the Acute Treatment of the Headache of Migraine

2005 Protocol: MT400-301: A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

2005 Protocol: A1601106: An Observation, Multiple-Attack Study in Migraineurs to determine the Incidence and Impact of Migraine Relapse and Recurrence Associated with 5HT agonist (Triptan) Treatment.

2005 Protocol: MT400-303: An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months

2005 Protocol: CAPSS-316: Efficacy and Safety of AXERT (Almotriptan Malate) Versus Placebo for the Acute Treatment of Migraine Headache

2005 Protocol: CAPSS-295: An Open-Label Study of the Safety and Efficacy of Topiramate for the Prophylaxis of Chronic Migraine: Extension Study To CAPSS-276

2005 Protocol: CAPSS-276: A Comparison of the Efficacy And Safety of Topiramate versus Placebo for the Prophylaxis of Chronic Migraine

2005 Protocol: 065-00: A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study To Examine the Efficacy of Rizatriptan 10mg Tablet Administered Early During a Migraine Attack while the Pain is Mild

2004 Protocol: CL1776-005: A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches

2004 Protocol: CXA20008: A Multicenter, Randomized, Double-Blind, Single-Dose, Parallel Group Pilot Study to Assess the Safety and Efficacy of the COX2 Inhibitor, GW406381 Versus Placebo and Naproxen Sodium Versus Placebo in the Treatment of Acute Migraine

2004 Protocol: SUM30047: A Randomized, Double-Blind Placebo-Controlled, Parallel-Group, Single Attack Study to Evaluate the Onset of Efficacy of Sumatriptan Fast Disintegrating Tablets (FDT) 50mg and 100mg

2004 Protocol: E2020-A001-212: A 20-Week, Multicenter Randomized, Double-Blind Comparison of the Efficacy and Safety of Aricept Versus Inderal LA in Migraine Prophylaxis

2003 Protocol: A1601080: A Multicenter, Double-Blind, Randomized, Placebo Controlled Study of Eletriptan (20 and 40 MG) Versus Placebo in the Early Treatment of Migraine

2003 Protocol: SUM20033: A Randomized, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study To Investigate the Efficacy and Tolerability of 100mg Sumatriptan Administered as a Film-Coated Fast Disintegrating Tablet

2003 Protocol: WL-1001-02-02: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache

2003 Protocol: A1A20004: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg compared to Placebo in Subjects with Peripheral Neuropathic Pain

2003 Protocol: 311CUS/0022: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG) Nasal Spray in The Acute Treatment of Adult Subjects with Migraine

2003 Protocol: H7B-MC-LXAG: A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Investigate the Safety and Efficacy of Two Doses of LY466195 and 6 mg Subcutaneous Sumatriptan in Patients with an Acute Migraine Attack

2003 Protocol: SUM40299: A Randomized, Double-Blind Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Tolerability of Oral Sumatriptan 25mg, 50mg, and 100mg tablets for a Single Moderate or Severe Headache in Adults Diagnosed with Migrainous Disorder

2002 Protocol: TOPMAT-MIGR-002: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine

PUBLICATIONS

Cook, C., Freeman, M., Ailani, J., et al. Towards a Standardized Process of Onboarding Advanced Practice Providers into Headache Medicine Practices in the United States: Expert Consensus from the American Headache Society Practice Management Committee. *Headache*, In Press (2025)

Freeman, M.C., 2025. Tetany. In: England, J.D. (Ed.), *Encyclopedia of the Neurological Sciences*, vol. 4. Elsevier, Academic Press, pp. 518–519.

Freeman, M., Cook, C., Ailani, J. et al. Towards a Standardized Process of Onboarding Advanced Practice Providers (APPs) into Headache Medicine Practices in the United States. American Academy of Neurology 77th Annual Meeting. April 2025. San Diego, CA.

Freeman, M. A Critical Overview of Neuromodulatory Devices for Migraine. 18th European Headache Congress. Rotterdam, Netherlands. December 2024.

Freeman, M. Guidelines for an Efficient New Patient Headache Evaluation. American Headache Society. August 2024. <https://welcome.ahsnet.org/page/Practice-Management-Special-Feature-Aug-24>

Freeman, M. Tetany. Reference Module in Neuroscience and Biobehavioral Psychology. Science Direct, Elsevier. 2024.
<https://www.sciencedirect.com/science/article/abs/pii/B9780323957021001809>

Freeman, M., Birlea, M., Cook, C. et al. Status of Advanced Practice Providers Onboarding and Training in Headache Medicine Practices in the United States: A Survey. Headache 2024; 64: S1 (P-515). American Headache Society 68th Annual Meeting. June 2024. San Diego, CA P-515

Freeman, M. Top 15 Business Strategies for Enhancing Your Onabotulinumtoxin-A (BOTOX) Migraine Clinic. American Headache Society. March 2024.
<https://welcome.ahsnet.org/general/custom.asp?page=Practice-Management-Special-Feature-Mar-24>

Agosti, R, Straube, A, Diener, HC, Freeman, M, et al. Efficacy, Tolerability, and Safety of OnabotulinumtoxinA Treatment for Chronic Migraine in Patients with Acute Medication Overuse: Analysis of the PREEMPT and COMPEL Trials. European Headache Congress 17th Annual Meeting. December 2023. Barcelona, Spain. (Encore presentation: Dreilaendertagung Kopfschmerz. April 2024. Interlaken, Switzerland). (Encore presentation: Swiss Neurological Society, June 2024, Basel, Switzerland) (Encore presentation: Société Française d'Etudes et de Traitement de la Douleur 24th annual meeting. November 2024. Lille France).

Freeman, M. (2021). Optimizing the Migraine Consultation. NeurologyLive 2021; 5(4):31-34.

Brandes, J; Diener, HC; Doležil, D; Freeman, M; McAllister, P; Winner, P; Klatt, J; Cheng, S; Zhang, F; Wen, S; Ritter, S; Lenz, R; Mikol, D. The Spectrum of Response to Erenumab in Patients With Chronic Migraine and Subgroup Analysis of Patients Achieving $\geq 50\%$, $\geq 75\%$, and 100% Response. Cephalalagia 2020 Jan;40(1):28-38

Winner P, Freeman M, Cohen J, Yang R, and Ning X. Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study. American Headache Society 61st Annual Scientific Meeting. July 2019. Philadelphia, PA. (encore presentation: American Neurological Association 144th Annual Meeting. October 2019. St. Louis, MO). (encore presentation: International Headache Society 19th Congress. September 2019. Dublin, Ireland)

Blumenfeld A, Stark RJ, Freeman MC, Orejudos A, and Adams AM. Long-Term Study of the Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine: COMPEL Study. *The Journal of Headache and Pain* 2018; 19:13

Cady R, Smith T, Biondi D, Berman G, Freeman M, et al. Eptinezumab Infusion Associated with Meaningful Reductions in Daily Migraine Activity on Day 1 and Over Weeks 1 Through 4 in Patients with Frequent Episodic Migraine: Results of the PROMISE-1 (Prevention of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial. *International Headache Society 18th Congress*. September 2017. Vancouver, Canada

Brandes J, Diener HC, Dolezil D, Freeman M, et al. Chronic Migraine Treatment with Erenumab: Responder Rates. *American Headache Society 59th Annual Scientific Meeting*. June 2017. Boston, MA. (encore presentation: 3rd Congress of the European Academy of Neurology. June 2017. Amsterdam, Netherlands)

Wilkinson P, Ade K, Rogers L, Attix D, Kuchibhatla M, Smith L, Laskowitz D, Freeman M, et al. Preventing Episodic Migraine with Caloric Vestibular Stimulation: A Randomized Controlled Trial. *Headache* 2017; 57: 1065-1087.

Freeman, M. (2017). Headache Devices. *Natural Triad Magazine*. July 2017.

Freeman, M. (2016). Concussion and Post-Traumatic Headache. *Natural Triad Magazine*. November 2016.

Freeman, M. (2016). Migraine Medication Update. *Natural Triad Magazine*. August 2016.

Black R, Rogers L, Ade K, Freeman M, et al. Caloric Vestibular Stimulation for the Prevention of Migraine Headache. Abstract and Poster Presentation. *58th Annual Scientific Meeting of the American Headache Society*. June 2016. San Diego, CA

Freeman, M. (2016): Migraine Surgery. *Natural Triad Magazine*. March 2016

Freeman, M. (2015). Headaches in Children. *Natural Triad Magazine*. November 2015

Freeman, M. Tetany. In: Aminoff M.J. and Daroff R.B. (eds.) *Encyclopedia of the Neurological Sciences*, 2nd edition, vol.4, p. 419. Oxford: Academic Press. 2014

Freeman, M. Myokymia. In: Aminoff M.J. and Daroff R.B. (eds.) *Encyclopedia of the Neurological Sciences*, 2nd edition, vol.3, p. 252. Oxford: Academic Press. 2014

Freeman, M. (2014). Cluster Headache: Treatment (part 2). *Natural Triad Magazine*. October 2014.

Freeman, M. (2014). Cluster Headache (part 1). *Natural Triad Magazine*. August 2014.

Freeman, M. (2013). Migraine Headache: Your Questions Answered. Natural Triad Magazine. October 2013.

Freeman, M. (2013). BOTOX and Chronic Migraine. Natural Triad Magazine. September 2013.

Freeman, M. (2013). Migraine Headache. Natural Triad Magazine. July 2013.

Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program. *Headache*. 2011;51:1358-1373.

Freeman M and Adelman J. *Secondary Headaches in Head, Face, and Neck Pain: Science, Evaluation and Management*. John Wiley & Sons, Inc. 2009

Aurora S, Winner P, Freeman M, et al. Botulinum Neurotoxin Type A for Treatment of Chronic Migraine: Pooled Analyses of the PREEMPT Clinical Program, Including 32-Week, Open-Label Phase (Poster Presentation, International Headache Society Meeting, Philadelphia, PA), September 2009

Freeman M, Taylor A, and Adelman J. Electronic Medical Record System in a Headache Specialty Practice: A Patient Satisfaction Survey. *Headache* 2009;47:212-215.

Taylor A, Adelman J, and Freeman M. Efficacy of Duloxetine as a Migraine Preventive Medication: Possible Predictors of Response in a Retrospective Chart Review. *Headache* 2007;47:1200-1203.

Freeman, M. Migraine Preventive Medications. *Headache & Pain* 2006;17(2):83-89

Freeman, M. Migraine Preventive Medications: Guidelines for Success. *Applied Neurology* 2006; 2:D1-D8.

Adelman J and Freeman, M. Early Intervention in Migraine Attacks: Making Sense of the Data. *Headache & Pain* 2005;16:109-115.

Adelman J, Adelman L, Freeman, M, et al. Cost Considerations of Acute Migraine Treatment. *Headache* 2004;44:271-285.

Adelman L, Adelman J, Freeman, M, Von Seggern, R. Pharmacoeconomics: The Cost of Prophylactic Migraine Treatments. *Headache* 2004;44:1-5.

Freeman M. Myokymia. In: *Encyclopedia of the Neurological Sciences* (M. Aminoff and R. Daroff, eds.). Academic Press 2003.

Freeman M. Tetany. In: Encyclopedia of the Neurological Sciences (M. Aminoff and R. Daroff, eds.). Academic Press 2003.

Freeman M, Weimer LH, Arnaudo E, Brust JCM. Neuropathic and autonomic effects of intramuscular podophyllin. *Ann Neurol* 1997;42:416.

Weimer LH, Arnaudo E, Freeman M, Brust JCM, Lovelace RE. Electrodiagnostic and autonomic findings after intramuscular podophyllin. *Muscle and Nerve* 1997;28:1059.